Advanced Hybrid Closed Loop System Early Feasibility Data on Patients Undergoing Unannounced Meal Challenges Shows Promising Results

Positive Data on Many Medtronic Innovations Presented at ATTD: Extended Wear Infusion Set Designed to Last Twice as Long, MiniMed 670G System Real-Life Performance in Europe, and ProCGM Use in Type 2 Diabetes Patients

DUBLIN, Feb. 24, 2020 (GLOBE NEWSWIRE) --  Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced a successful conclusion to the 13th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2020), which took place in Madrid, Spain, from February 19 - 22, 2020.

At this year's conference, the Diabetes Group at Medtronic presented a range of scientific data focusing on the company’s:

•  Advanced hybrid closed loop system which is currently in pivotal trials and aims to improve patient experience and outcomes;
•  Latest extended wear infusion set technology, which is designed to last at least twice as long as current infusion sets while providing comfort of wear;
•  MiniMed 670G system real-world data in Europe, which showed the hybrid closed loop system is delivering improved glycemic control across all glucose ranges in clinical and real-world settings; and
•  Professional CGM (proCGM), with cost-effectiveness data showing the potential of the device’s economic value in people with type 2 diabetes.

"Medtronic is committed to driving product innovation that prioritizes clinical outcomes and improves patient experience," said Dr. Robert Vigersky, chief medical officer, Global Medical and Clinical Affairs for Diabetes Group at Medtronic. "These data underscore our commitment to continually creating new technologies that improve time in range and mean sensor glucose, reduce highs and lows, and just as importantly reduce the work of living with diabetes."

Here is a recap of the major scientific data presentations on Medtronic innovation that took place at ATTD 2020:

Advanced Hybrid Closed Loop Scientific Data

• “Unannounced Meal Challenges in a Protected Free Living Environment Using the AHCL System”
• “Missed and Late Meal Boluses with Faster Acting Insulin Aspart (Fiasp) vs. Insulin Aspart Using the Medtronic Advanced Hybrid Closed Loop System”

The advanced hybrid closed loop (AHCL) system is designed to combine automated basal (background) insulin delivery with automatic correction boluses. The AHCL system will also feature an adjustable target glucose as low as 100 mg/dL (5.5 mmol/L), the lowest amongst any automated insulin delivery system, for the first time. Compared with the MiniMed 670G system, the AHCL algorithm demonstrated an increased time spent in target glucose range of 70-180 mg/dL (3.9-10 mmol/L) and a reduction in post prandial excursions in feasibility studies.